
Assess long‐term efficacy and safety of guselkumab, an IL‐23p19‐subunit inhibitor, in patients with active psoriatic arthritis (PsA) from the Phase‐3 DISCOVER‐2 trial. In DISCOVER‐2, patients with active PsA (≥5 swollen and ≥5 tender joints; CRP ≥0.6 mg/dL) despite prior nonbiologic therapy were randomized to: guselkumab 100mg every‐4‐weeks (Q4W); at Week0, Week4, and Q8W; or placebo➔guselkumab Q4W at Week24. Efficacy assessments included ≥20%/50%/70% improvement in ACR components (ACR20/50/70), Investigator’s Global Assessment of psoriasis score=0 (IGA=0; indicating complete skin clearance), enthesitis (Leeds Enthesitis Index) and dactylitis (Dactylitis Severity Score) resolution, and changes in PsA‐modified van der Heijde‐Sharp (vdH‐S) radiographic scores...
Like
Save
Share